Company / Gross Profit per Share
Acadia Pharmaceuticals Gross Profit per Share History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit per Share
$4.23
FY2023
5-year range
$2.96 / $4.23
FY2019-FY2023
Trend
+34.2%
vs FY2022
Sector context
#17 of 29
Health Care
What the data says
At $4.23, Acadia Pharmaceuticals's gross profit per share ranks #17 of 29 in the Health Care sector. Gross Profit per Share has increased for 7 consecutive years, from $0.14 in FY2016 to $4.23 in FY2023.
Based on SEC 10-K filings.
4.23 in FY2023 with a 5-year CAGR of +20.0%.
Improved from $2.96 to $4.23 over the past 2 years.
Health Care sector context is included.
Gross Profit per Share over time
Growth rates
- 3-Year CAGR
- +15.0%
- 5-Year CAGR
- +20.0%
- 10-Year CAGR
- -
Sector benchmark
#17 of 29 in Health CareTop 59% of 29This company $4.23 Sector average $8.11
▼
-47.9% below sector average
Key checks
Key Insights
- Acadia Pharmaceuticals's gross profit per share has grown for 7 consecutive years.
- In FY2023, gross profit per share increased 34.2% year-over-year.
- Ranks #17 out of 29 companies in the Health Care sector.
- Lowest gross profit per share in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross Profit per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $4.23 | +34.2% |
| FY2022 | $3.15 | +6.2% |
| FY2021 | $2.96 | +6.7% |
| FY2020 | $2.78 | +22.0% |
| FY2019 | $2.28 | +34.1% |
| FY2018 | $1.70 | +78.1% |
| FY2017 | $0.95 | +582.6% |
| FY2016 | $0.14 | - |
As of FY2023 · SEC 10-K · Updated Jul 1, 2026